Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6943959 | 1.00 | TACR1 (0.62) | TACR1LMNAACHESIGMAR1GRIN1 | |
| SCHEMBL467266 | 1.00 | TACR1 (0.62) | TACR1LMNAACHESIGMAR1GRIN1 | |
| Hydrochloric Acid SCHEMBL10382846 | 0.98 | LMNA (0.64) | TACR1LMNAACHESIGMAR1GRIN1 | |
| Iodide SCHEMBL8816299 | 0.98 | TACR1 (0.61) | TACR1LMNAACHESIGMAR1GRIN1 | |
| SCHEMBL20274753 | 0.86 | ACHE (0.63) | TACR1ACHESIGMAR1MC4RBCHE | |
| SCHEMBL9466471 | 0.84 | ACHE (0.54) | TACR1LMNAACHESIGMAR1 | |
| SCHEMBL9379752 | 0.83 | ACHE (0.50) | TACR1LMNAACHESIGMAR1MC4R | |
| SCHEMBL6230149 | 0.82 | LMNA (0.46) | TACR1LMNAACHEBCHE | |
| SCHEMBL31193852 | 0.81 | TACR1 (0.59) | TACR1LMNAACHESIGMAR1GRIN1 | |
| SCHEMBL1339508 | 0.81 | TACR1 (0.59) | TACR1LMNAACHESIGMAR1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724162-B1 | INTERMEDIATES FOR OPTICALLY ACTIVE PIPERIDINE DERIVATIVES AND PREPARATION METHODS THEREOF | HK INNO N CORP (KR) | 2023-10-11 | — | — | EP | claimed |
| CN-115010652-A | Synthesis process of piperidine derivative intermediate | 苏州诚和医药化学有限公司 | 2022-09-06 | — | — | CN | claimed |
| CN-111587240-B | Intermediate of optically active piperidine derivative and process for producing the same | 怡诺安有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-115010652-A | Synthesis process of piperidine derivative intermediate | 苏州诚和医药化学有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-115010652-A | Synthesis process of piperidine derivative intermediate | 苏州诚和医药化学有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-111587240-A | Intermediate of optically active piperidine derivative and process for producing the same | 怡诺安有限公司 | 2020-08-25 | — | — | CN | disclosed |
| US-RE45364-E1 | Cyclic amine compound and pest control agent | NIPPON SODA CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| EP-1731518-B1 | CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT | NIPPON SODA CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| EP-2650290-A1 | Cyclic amine compound and pest control agent | NIPPON SODA CO., LTD. (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8101768-B2 | Cyclic amine compound and pest control agent | NIPPON SODA CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| EP-2367830-A1 | 1-OXA-8-AZASPIRO [4, 5] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030176461-A1 | Aminopiperidines | NPS ALLELIX CORP. (CANADA CORPORATION) (CA) | 2003-09-18 | — | — | US | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| EP-1296950-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS Allelix Corp. (CA) | 2003-04-02 | — | — | EP | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| WO-2001081308-A2 | AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS | NPS ALLELIX CORP. (CA) | 2001-11-01 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | TACR1 3658/4885LMNA 2388/4885ACHE 3357/4885 |
| US-20030176461-A1 | Aminopiperidines | SLC1A2, SLC6A4, SLC1A1 | TACR1 324/4885LMNA 2941/4885ACHE 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.